TY - JOUR
T1 - Association between the mutational smoking signature and the immune microenvironment in lung adenocarcinoma
AU - Sato, Kei
AU - Mimaki, Sachiyo
AU - Yamashita, Riu
AU - Togashi, Yosuke
AU - Naito, Tomoyuki
AU - Udagawa, Hibiki
AU - Katsumata, Shinya
AU - Nakasone, Shoko
AU - Miyoshi, Tomohiro
AU - Tane, Kenta
AU - Aokage, Keiju
AU - Sugano, Masato
AU - Kojima, Motohiro
AU - Fujii, Satoshi
AU - Kuwata, Takeshi
AU - Ochiai, Atsushi
AU - Goto, Koichi
AU - Tsuboi, Masahiro
AU - Tsuchihara, Katsuya
AU - Ishii, Genichiro
N1 - Funding Information:
This study was supported in part by the Advanced Research for Medical Products Mining Programme of the National Institute of Biomedical Innovation (NIBIO) , National Cancer Center Research and Development Fund ( 25-A-6 and 28-A-9 ) and JSPS KAKENHI ( 18K19488 ).
Funding Information:
This study was supported in part by the Advanced Research for Medical Products Mining Programme of the National Institute of Biomedical Innovation (NIBIO), National Cancer Center Research and Development Fund (25-A-6 and 28-A-9) and JSPS KAKENHI (18K19488).
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2020/9
Y1 - 2020/9
N2 - Objectives: Mutational signatures associated with tobacco smoking (mutational smoking signatures: SS) are characterized mainly by C > A mutations. The aim of this study was to characterize the association between the tumor immune microenvironment and the SS in lung adenocarcinoma. Methods: Lung adenocarcinomas surgically resected from 96 patients, for which whole exome sequencing data was available, were included in the study. We extracted the SS from whole exome sequencing data, calculated the weights of SS using deconstructSigs, and compared the clinicopathological features of SS positive (SS+) and negative (SS-) adenocarcinomas. We selected 18 tumor pairs from SS + and SS- adenocarcinomas (sex, EGFR mutation, and tumor size-matched) and examined the expression of five immune markers (CD20, CD8, FOXP3, CD204, and PD-L1) by immunohistochemistry. Results: Of 96 specimens, there were 33 (34 %) SS + adenocarcinoma tumors. The smoking index significantly correlated with the weight of the SS (R = 0.43). Between SS + and SS- tumors, there was no significant difference in clinicopathological factors excluding smoking history. Immunohistochemistry revealed that the number of FOXP3 + T cells in SS + adenocarcinomas was significantly higher than that in the SS- adenocarcinomas (median number 58 vs. 36, p < 0.01). Also, the number of CD20 + B cells in SS + adenocarcinomas was significantly higher than that in the SS- adenocarcinomas (median number 77 vs. 29, p < 0.01); however; these phenomena could not be confirmed when stratified by smoking history. Conclusion: In lung adenocarcinoma, SS is associated with an immunosuppressive tumor microenvironment.
AB - Objectives: Mutational signatures associated with tobacco smoking (mutational smoking signatures: SS) are characterized mainly by C > A mutations. The aim of this study was to characterize the association between the tumor immune microenvironment and the SS in lung adenocarcinoma. Methods: Lung adenocarcinomas surgically resected from 96 patients, for which whole exome sequencing data was available, were included in the study. We extracted the SS from whole exome sequencing data, calculated the weights of SS using deconstructSigs, and compared the clinicopathological features of SS positive (SS+) and negative (SS-) adenocarcinomas. We selected 18 tumor pairs from SS + and SS- adenocarcinomas (sex, EGFR mutation, and tumor size-matched) and examined the expression of five immune markers (CD20, CD8, FOXP3, CD204, and PD-L1) by immunohistochemistry. Results: Of 96 specimens, there were 33 (34 %) SS + adenocarcinoma tumors. The smoking index significantly correlated with the weight of the SS (R = 0.43). Between SS + and SS- tumors, there was no significant difference in clinicopathological factors excluding smoking history. Immunohistochemistry revealed that the number of FOXP3 + T cells in SS + adenocarcinomas was significantly higher than that in the SS- adenocarcinomas (median number 58 vs. 36, p < 0.01). Also, the number of CD20 + B cells in SS + adenocarcinomas was significantly higher than that in the SS- adenocarcinomas (median number 77 vs. 29, p < 0.01); however; these phenomena could not be confirmed when stratified by smoking history. Conclusion: In lung adenocarcinoma, SS is associated with an immunosuppressive tumor microenvironment.
KW - Cigarette smoking
KW - Immune microenvironment
KW - Lung adenocarcinoma
KW - Smoking signature
KW - Whole exome sequencing
UR - http://www.scopus.com/inward/record.url?scp=85087684687&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087684687&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2020.06.029
DO - 10.1016/j.lungcan.2020.06.029
M3 - Article
C2 - 32652369
AN - SCOPUS:85087684687
SN - 0169-5002
VL - 147
SP - 12
EP - 20
JO - Lung Cancer
JF - Lung Cancer
ER -